Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19.

Fecha de publicación: 01/03/2022 Fecha Ahead of Print: 18/02/2022

Autores de IIS La Fe

• Juan Francisco Merino Torres

  Autor

Participantes ajenos a IIS La Fe

• Carrasco-Sánchez FJ
• Carretero-Anibarro E
• Gargallo MÁ
• Gómez-Huelgas R
• Orozco-Beltrán D
• Pines Corrales PJ
• Ruiz Quintero MA

Grupos

• Unidad Mixta de Investigación en Endocrinología, Nutrición y Dietética clínica

  Leader

  Juan Francisco Merino Torres

Abstract

BACKGROUND: This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic. MATERIALS AND METHODS: A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus. RESULTS: Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and the need for mechanical ventilation (evidence 2b). CONCLUSIONS: The use of iDPP-4 appears to be safe in patients with COVID-19, and quality studies are needed to clarify their possible advantages further.

Copyright © 2021 SEEN and SED. Published by Elsevier España, S.L.U. All rights reserved.

Keywords

• Antidiabetic drugs; COVID-19; Diabetes; Fármacos antidiabéticos; Mortalidad; Mortality; iDPP-4